Eli Lilly & Company and Biosite® Incorporated announced their collaboration on a clinical trial employing a tailored therapy strategy for Lilly's severe sepsis drug, Xigris® (drotrecogin alfa [activated]). The trial will investigate the use of a multipurpose biomarker (Protein C) to be used in connection with the administration of Xigris®: RESPOND (Research Evaluating Serial Protein C levels in severe sepsis patients ON Drotrecogin alfa).
Under the terms of the agreement, Biosite will develop a rapid, point-of-care diagnostic capable of measuring Protein C levels. Lilly will use the Biosite test, as well as other existing FDA approved Protein C tests, to enroll patients in its upcoming Phase II-b clinical trial, which is expected to begin in the fourth quarter of 2006. Investigators also will use the tests in this novel study to help with individualized dose and duration of Xigris® therapy and to evaluate patient response. The agreement also grants Biosite rights to intellectual property in the field of sepsis diagnosis, including assignment of U.S. Patent Application No. 10/759,216 Biomarkers for Sepsis. The financial terms of the agreement were not disclosed.
Sepsis is a severe illness caused by overwhelming infection of the bloodstream by toxin-producing bacteria while Xigris® (drotrecogin alfa [activated]) is a recombinant form of human Activated Protein C administered by intravenous infusion. Executives of the two collaborating companies hope that this biomarker strategy will help maximize the value of Xigris® for critically ill sepsis patients.
Well said,i applaud your blog,mental health consumers are the least capable of self advocacy,my doctors made me take zyprexa for 4 years which was ineffective for my symptoms.I now have a victims support page against Eli Lilly for it's Zyprexa product causing my diabetes.--Daniel Haszard www.zyprexa-victims.com
Posted by: Daniel Haszard | June 5, 2006 2:08 PM | Permalink to Comment